The role of neoadjuvant chemotherapy for breast cancer treatment

Tadashi Ikeda, Hiromitsu Jinno, Akira Matsui, Shigeru Masamura, Masaki Kitajima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalBreast Cancer
Volume9
Issue number1
DOIs
Publication statusPublished - 2002 Jan

Fingerprint

Breast Neoplasms
Drug Therapy
Segmental Mastectomy
Therapeutics
Large-Core Needle Biopsy
Residual Neoplasm
Combination Drug Therapy
Breast
Survival Rate
Recurrence
Survival
Neoplasms

Keywords

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Ikeda, T., Jinno, H., Matsui, A., Masamura, S., & Kitajima, M. (2002). The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer, 9(1), 8-14. https://doi.org/10.1007/BF02967540

The role of neoadjuvant chemotherapy for breast cancer treatment. / Ikeda, Tadashi; Jinno, Hiromitsu; Matsui, Akira; Masamura, Shigeru; Kitajima, Masaki.

In: Breast Cancer, Vol. 9, No. 1, 01.2002, p. 8-14.

Research output: Contribution to journalArticle

Ikeda, T, Jinno, H, Matsui, A, Masamura, S & Kitajima, M 2002, 'The role of neoadjuvant chemotherapy for breast cancer treatment', Breast Cancer, vol. 9, no. 1, pp. 8-14. https://doi.org/10.1007/BF02967540
Ikeda T, Jinno H, Matsui A, Masamura S, Kitajima M. The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer. 2002 Jan;9(1):8-14. https://doi.org/10.1007/BF02967540
Ikeda, Tadashi ; Jinno, Hiromitsu ; Matsui, Akira ; Masamura, Shigeru ; Kitajima, Masaki. / The role of neoadjuvant chemotherapy for breast cancer treatment. In: Breast Cancer. 2002 ; Vol. 9, No. 1. pp. 8-14.
@article{9eb7385a9d764677a9ae7fb8877183c4,
title = "The role of neoadjuvant chemotherapy for breast cancer treatment",
abstract = "Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.",
keywords = "Breast cancer, Neoadjuvant chemotherapy, Preoperative chemotherapy",
author = "Tadashi Ikeda and Hiromitsu Jinno and Akira Matsui and Shigeru Masamura and Masaki Kitajima",
year = "2002",
month = "1",
doi = "10.1007/BF02967540",
language = "English",
volume = "9",
pages = "8--14",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - The role of neoadjuvant chemotherapy for breast cancer treatment

AU - Ikeda, Tadashi

AU - Jinno, Hiromitsu

AU - Matsui, Akira

AU - Masamura, Shigeru

AU - Kitajima, Masaki

PY - 2002/1

Y1 - 2002/1

N2 - Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.

AB - Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.

KW - Breast cancer

KW - Neoadjuvant chemotherapy

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036051734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036051734&partnerID=8YFLogxK

U2 - 10.1007/BF02967540

DO - 10.1007/BF02967540

M3 - Article

VL - 9

SP - 8

EP - 14

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -